Bradykinin in the treatment of arterial hypertension: Friend or foe?

Hellenic Journal of Cardiology

Volumn 53, Issue 2, 2012, Pages 91-94

  Marketou, Maria E ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Angiotensin; Arterial hypertension; Bradykinin

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; RAMIPRIL;

ADRENERGIC SYSTEM; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROMATOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COUGHING; DRUG HALF LIFE; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; KIDNEY VASCULAR RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PRESSORECEPTOR; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE RELAXATION; SODIUM RETENTION; SYSTEMIC VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; BRADYKININ; HUMANS; HYPERTENSION; MICE; RATS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 84859997799     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol. 1996; 28: 803-812.
2. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001; 37: 1047-1052.
3. Vanhoutte PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension. 1989; 13: 658-667.
4. Regoli D. Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol. 1984; 6 Suppl 2: S401-412.
5. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the b (1) bradykinin receptor in normotension and hypertension. Circ Res. 2001; 88: 275-281.
6. Farmer SG, Burch RM, Meeker SA, Wilkins DE. Evidence for a pulmonary B3 bradykinin receptor. Mol Pharmacol. 1989; 36: 1-8.
7. Saha JK, Sengupta JN, Goyal RK. Effect of bradykinin on opossum esophageal longitudinal smooth muscle: evidence for novel bradykinin receptors. J Pharmacol Exp Ther. 1990; 252: 1012-1020.
8. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980; 32: 1-46.
9. Mattson DL, Cowley AW. Kinin actions on renal papillary blood flow and sodium excretion. Hypertension. 1993; 21: 961-965.
10. McGiff JC, Itskovitz HD, Terragno NA. The actions of bradykinin and eledoisin in the canine isolated kidney: relationships to prostaglandins. Clin Sci Mol Med. 1975; 49: 125-131.
11. D'Orléans-Juste P, de Nucci G, Vane JR. Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. Br J Pharmacol. 1989; 96: 920-926.
12. Pasquié JL, Herizi A, Jover B, Mimran A. Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Hypertension. 1999; 33: 830-834.
13. Mills IH. Renal kallikrein and regulation of blood pressure in man. In Erdos DG, editor. Bradykinin, Kallidin and Kallikrein. New York: Springer Verlag; 1979. p. 549-567.
14. Katori M, Majima M. Role of the renal kallikrein-kinin system in the development of hypertension. Immunopharmacology. 1997; 36: 237-242.
15. Benetos A, Gavras I, Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension. 1986; 8: 1089-1092.
16. Waeber B, Aubert JF, Vavrek R, Stewart JM, Nussberger J, Brunner HR. Role of bradykinin in blood pressure regulation of conscious spontaneously hypertensive rats. J Hypertens. 1988; 4 (Suppl 6): S597-S598.
17. Wang DZ, Chao L, Chao J. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 1997; 29: 488-493.
18. Madeddu P, Varoni MV, Palomba D, et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation. 1997; 96: 3570-3578.
19. Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 1997; 29: 483-487.
20. Emanueli C, Fink E, Milia AF, et al. Enhanced blood pressure sensitivity to deoxycorticosterone in mice with disruption of bradykinin B2 receptor gene. Hypertension. 1998; 31: 1278-1283.
21. Milan A, Mulatero P, Williams TA, et al. Bradykinin B2 receptor gene (-58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients. J Hypertens. 2005; 23: 63-69.
22. Pretorius MM, Gainer JV, Van Guilder GP, et al. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther. 2008; 83: 122-129.
23. Dhamrait SS, Payne JR, Li P, et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003; 24: 1672-1680.
24. Aoki S, Mukae S, Itoh S, et al. The genetic factor in acute myocardial infarction with hypertension. Jpn Circ J. 2001; 65: 621-626.
25. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007; 28: 1383-1389.
26. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47: 25-49.
27. Oeseburg H, Iusuf D, van der Harst P, van Gilst WH, Henning RH, Roks AJ. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension. 2009; 53: 417-422.
28. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res. 2000; 87: 540-542.
29. Kintsurashvili E, Duka A, Ignjacev I, Pattakos G, Gavras I, Gavras H. Age-related changes of bradykinin B1 and B2 receptors in rat heart. Am J Physiol Heart Circ Physiol. 2005; 289: H202-205.
30. Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H. Cardioprotective effects of a selective B (2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens. 2010; 23: 562-568.
31. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47: 25-49.
32. Dendorfer A, Wolfrum S, Dominiak P. Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jpn J Pharmacol. 1999; 79: 403-426.
33. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002; 359: 2088-2089.
34. Sharma JN, Stewart JM, Mohsin SS, Katori M, Vavrek R. Influence of a kinin antagonist on acute hypotensive responses induced by bradykinin and captopril in spontaneously hypertensive rats. Agents Actions Suppl. 1992; 38: 258-269.
35. Sabatini RA, Guimarães PB, Fernandes L, et al. ACE activity is modulated by kinin B2 receptor. Hypertension. 2008; 51: 689-695.
36. Linz W, Schölkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992; 105: 771-772.
37. Rhaleb NE, Yang XP, Scicli AG, Carretero OA. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension. 1994; 23: 865-868.
38. Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA, Catelli De Carvalho MH. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension. 2001; 37: 703-709.
39. Campbell DJ, Zhang Y, Kelly DJ, et al. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol. 2011; 38: 623-631.
40. Bélanger S, Bovenzi V, Côté J, et al. Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides. 2009; 30: 777-787.